Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2020-08-05
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MINIject Glaucoma Implant in European Patients
NCT03624361
A Study Evaluating the Safety and Efficacy of MINIject S+ in Subjects With Open Angle Glaucoma
NCT07009236
MINIject in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications
NCT03193736
Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.
NCT05024695
MINIject (MINI SO627) in Patients With Open Angle Glaucoma Using Single Operator Delivery Tool
NCT04517786
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Minimally invasive glaucoma surgery (MIGS)
MINIject implant placed into supraciliary space. The implantation was done in a previous study in which patient participated and is not part of this study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient continues to have MINIject implanted at the point of enrolment
* Patient must provide written informed consent to participate
Exclusion Criteria
* Patient who is unwilling to return to the study visits and undergo study assessments, as required by clinical study protocol
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
iSTAR Medical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zubair Hussain, PhD
Role: STUDY_DIRECTOR
iSTAR Medical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinica Oftalmologica del Caribe
Barranquilla, , Colombia
Center Hospotalier Universitaire Genoble Alpes
Grenoble, , France
Hopital de la Croix-Rousse
Lyon, , France
Uniklinik Köln
Cologne, North Rhine-Westphalia, Germany
Universitätsklinikum Mainz
Mainz, Rhineland-Palatinate, Germany
Klinikum der Universität München
München, , Germany
Maxivision Eye Hospital
Hyderabad, Telangana, India
Panama Eye Center
Panama City, , Panama
Hospital Clínico San Carlos
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jose Luis Rodriguez, MD
Role: primary
Marc Mackert, MD.
Role: primary
Anitha Kamarthy, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STAR-GLOBAL (ISM09)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.